journal article Open Access Dec 01, 2022

Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study

View at Publisher Save 10.1111/bjd.21767
Abstract
Abstract

Background
Recap of atopic eczema (RECAP) is a patient-reported outcome measure assessing eczema control. This instrument has been developed and validated in the UK. There are self-reported and proxy-reported versions in English, Dutch and German. However, it is unclear whether the self-reported version shows adequate content validity when completed by young people (8–16 years) in these languages.


Objectives
To assess the content validity (comprehensibility, relevance and comprehensiveness) of the English, German and Dutch versions of the self-reported RECAP in young people with atopic eczema and to identify the most appropriate age cutoff for self-completion.


Methods
We conducted 23 semistructured cognitive interviews with young people aged 8–16 years, using the ‘think-aloud’ method. In Germany and the Netherlands, participants were recruited in dermatology clinics and in the UK through social media and existing mailing lists. Interviews were audio recorded, transcribed verbatim and analysed in the three languages, using a problem-focused coding manual. Transcripts were coded by two independent reviewers in each country. Themes were translated into English and compared across the three countries.


Results
Significant age-related comprehensibility issues with the last three items of the questionnaire occurred with young people aged 8–11 years, causing difficulties completing RECAP without help. However, older children had only minor problems and were able to complete the questionnaire by themselves. The self-reported version of RECAP has sufficient content validity for self-completion in young people aged 12 years and above. However, the German version with some translational adaptations may be appropriate for children from the age of 8 years. There may be some situations where the proxy version is needed for older children too.


Conclusions
The self-reported version of RECAP is appropriate for use from the age of 12 years. The proxy version can be used in children younger than 12 years. Other measurement properties should be further investigated.
What is already known about this topic?  Recap of atopic eczema (RECAP) is an instrument recommended by the Harmonising Outcome Measures for Eczema initiative for the core outcome domain of long-term control of atopic eczema.Content validity of RECAP for self-completion by adults and of the proxy version has been assessed.
What does this study add?  In this study, content validity (comprehensibility, relevance and comprehensiveness) of the self-reported version of RECAP among young people (aged 8–16 years) with atopic eczema across the UK, Germany and the Netherlands is assessed.Based on these findings, key recommendations on how to measure eczema control in young people with atopic eczema are formulated.
What are the clinical implications of this work?  The Dutch, English and German self-completion versions of RECAP are recommended for use in adolescents from the age of 12 years.The proxy version could be used in children younger than 12 years or where children are cognitively or physically incapable of reporting their experience of eczema control.Caregivers should be encouraged to complete RECAP together with their child where possible.
Topics

No keywords indexed for this article. Browse by subject →

References
29
[1]
Guidelines of care for the management of atopic dermatitis

Lawrence F. Eichenfield, Wynnis L. Tom, Sarah L. Chamlin et al.

Journal of the American Academy of Dermatology 2014 10.1016/j.jaad.2013.10.010
[2]
Nemeth
[3]
Deckers "Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies" PLOS ONE (2012) 10.1371/journal.pone.0039803
[4]
Bieber "Atopic dermatitis" Ann Dermatol (2010) 10.5021/ad.2010.22.2.125
[5]
Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis

Eric L. Simpson, Emma Guttman-Yassky, David J. Margolis et al.

JAMA Dermatology 2018 10.1001/jamadermatol.2018.1572
[6]
Barbarot "Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review" J Am Acad Dermatol (2016) 10.1016/j.jaad.2016.05.043
[7]
Marshall "Impact of patient-reported outcome measures on routine practice: a structured review" J Eval Clin Pract (2006) 10.1111/j.1365-2753.2006.00650.x
[8]
Howells "Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema" J Eur Acad Dermatol Venereol (2019) 10.1111/jdv.15475
[9]
Thomas "Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting" Br J Dermatol (2021) 10.1111/bjd.19751
[10]
Bhanot "Assessing the validity, responsiveness and reliability of the Recap measure of eczema control" Br J Dermatol (2021) 10.1111/bjd.19709
[11]
Bhanot "Validation of the RECap of AtoPic eczema measure of eczema control for use in dermatology clinics" Clin Exp Dermatol (2022) 10.1111/ced.14934
[12]
Gabes "The German RECAP questionnaire: linguistic validation and cognitive debriefing in German adults with self-reported atopic eczema and parents of affected children" J Patient Rep Outcomes (2021) 10.1186/s41687-021-00285-2
[13]
Howells "Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP)" Br J Dermatol (2020) 10.1111/bjd.18780
[14]
Annett "Factors influencing parent reports on quality of life for children with asthma" J Asthma (2003) 10.1081/jas-120019030
[15]
Theunissen "The proxy problem: child report versus parent report in health-related quality of life research" Qual Life Res (1998) 10.1023/a:1008801802877
[16]
Groot "Adolescents’ experiences with patient engagement in respiratory medicine" Pediatr Pulmonol (2021) 10.1002/ppul.25150
[17]
Matza "Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force" Value Health (2013) 10.1016/j.jval.2013.04.004
[18]
EuroQol Research Foundation
[19]
Fonteyn "A description of think aloud method and protocol analysis" Qual Health Res (1993) 10.1177/104973239300300403
[20]
COSMIN
[21]
University of Nottingham
[22]
Grant "Skin picking disorder" Am J Psychiatry (2012) 10.1176/appi.ajp.2012.12040508
[23]
Dumontheil "Development of abstract thinking during childhood and adolescence: the role of rostrolateral prefrontal cortex" Dev Cogn Neurosci (2014) 10.1016/j.dcn.2014.07.009
[24]
Chu "Treatments for childhood atopic dermatitis: an update on emerging therapies" Clin Rev Allergy Immunol (2021) 10.1007/s12016-020-08799-1
[25]
US Food and Drug Administration
[27]
Leshem "Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative" J Am Acad Dermatol (2020) 10.1016/j.jaad.2019.12.055
[28]
Naka "Clinical trials: kids are not just little people" Clin Dermatol (2017) 10.1016/j.clindermatol.2017.08.008
[29]
Pariser "Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)" Curr Med Res Opin (2020) 10.1080/03007995.2019.1699516
Metrics
9
Citations
29
References
Details
Published
Dec 01, 2022
Vol/Issue
187(6)
Pages
919-926
License
View
Authors
Cite This Article
Michaela Gabes, Aviël Ragamin, Arabella Baker, et al. (2022). Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study. British Journal of Dermatology, 187(6), 919-926. https://doi.org/10.1111/bjd.21767